Business
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares
April 7, 2026
The Motley Fool
Scroll
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock.
The Motley Fool
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left